ENTITY
Clover Biopharmaceuticals

Clover Biopharmaceuticals (2197 HK)

45
Analysis
Health CareChina
Clover Biopharmaceuticals Limited operates as a clinical-stage biotechnology company. The Company develops novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases. Clover Biopharmaceuticals provides services worldwide.
more
bullishNongfu Spring
20 Feb 2022 04:23

Index Rebalance & ETF Flow Recap: HSI, HSCEI, HSTECH, HSCI, S&P/ASX, SET50, LIC, SBI Sumishin, Crown

This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...

Logo
489 Views
Share
19 Feb 2022 11:30

HSCI Index Rebalance: 29 Adds, 12 Deletes & Changes to Stock Connect

There are 29 adds & 12 deletes for the HSCI at the March rebal. 26 of the inclusions will join Southbound Stock Connect while all the deletes will...

Logo
492 Views
Share
bullishSenseTime Group
25 Jan 2022 08:58

HSCI Index Rebalance and Stock Connect: Plenty of New Listings Should Be Included

There could be up to 34 adds and 22 deletes for the HSCI in March based on market cap, liquidity and prolonged suspensions. A lot of new listings,...

Logo
524 Views
Share
bearishGushengtang
09 Dec 2021 14:46

Gushengtang IPO Trading - Priced at Top End with Lukewarm Subscription Rates

Gushengtang (GUS HK) raised around US$104m after pricing its IPO at HKD29.0/share, at the top end of the IPO price range.

Logo
385 Views
Share
08 Dec 2021 12:18

HSCI Index Rebalance and Stock Connect: More Inclusions than Exclusions in March

We expect there will be a lot more inclusions than exclusions at the March rebalance of the HSCI. The changes to the index will result in changes...

Logo
474 Views
Share
x